Quince Sets October 6 Vote on 94% Dilutive Series C Conversion and Leadership Change
QNCX has more than doubled off its 52-week low of $15.1 on light trading volume (0.2× avg).
Summary
Quince Therapeutics' definitive proxy sets an October 6 vote on converting Series C Preferred Stock into 10.99M common shares, a 94% dilution event tied to the Orphai acquisition and $115M PIPE. The vote also triggers a leadership change to the Orphai team.
Key Events · Corporate Governance and Compliance · QNCX
-
Special Meeting Set for October 6
Definitive proxy filed with record date August 24, 2026 and meeting date October 6, 2026. Stockholders vote on six proposals including Series C conversion, authorized share increase, and new equity plans.
-
94% Dilution from Series C Conversion
Conversion of 211,301.868 Series C Preferred shares into 10,987,728 common shares would increase outstanding shares from 1,017,063 to 12,004,791. Existing holders' ownership would drop from 6.9% to a fraction of that.
-
Cash Settlement Risk if Vote Fails
If Required Company Stockholder Matters are not approved by November 18, 2026, Series C holders can demand cash settlement at fair value. With $115.98M in cash and a $75.5M Q2 loss, this could be catastrophic.
-
Leadership Change to Orphai Team
CEO Dirk Thye and COO Brendan Hannah resign effective two business days after the meeting. Brigette Roberts becomes CEO, John Militello CFO, and Keith Fandrick COO. Thye and Hannah receive $700K and $500K retention bonuses respectively.
Analysis · QNCX · Life Sciences
Quince Therapeutics has finalized its special meeting for October 6, 2026, where stockholders will vote on converting Series C Preferred Stock into 10,987,728 common shares — a move that would increase the outstanding share count from 1,017,063 to 12,004,791, or roughly 94% dilution for existing holders. The conversion is tied to the May 2026 Orphai acquisition and $115M PIPE, and if the proposals fail, the company could face cash settlement obligations on the preferred stock after November 18, 2026. The proxy also confirms the planned CEO and COO resignations, with Brigette Roberts, John Militello, and Keith Fandrick stepping into the top roles. Against the backdrop of a $75.5M Q2 loss and going-concern warning, this vote is effectively a referendum on the company's survival structure.
How filings like this one have moved
In the 30 days to Aug 25, 2026, 37.4% of the 3413 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, QNCX was trading at $31.78 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $34.1M. The 52-week trading range was $15.10 to $909.98. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.